Chart-Typ:
Zeitraum:
| XFRA PBN0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| XFRA PBN0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILALTERITY THERAP.ADR/600... ► Artikel lesen |
| XFRA NEW INSTRUMENTS AVAILABLE ON 20.08.2025 | The following instruments on XETRA do have their first trading 20.08.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.08.2025
Aktien
1 US02155X2053 Alterity Therapeutics... ► Artikel lesen |
| SurgePays Accelerates Growth Across All Business Verticals; Reports Q2 2025 Results and Issues Revenue Guidance of $75M to $90M in 2025 and $225M to $240M in 2026 | BARTLETT, Tenn., Aug. 13, 2025 /PRNewswire/ -- SurgePays, Inc. (Nasdaq: SURG) ("SurgePays" or the "Company"), a wireless and point-of-sale technology company... ► Artikel lesen |
| SurgePays Reports First Quarter 2025 Financial Results | AT&T Integration Complete; Nationwide Launch Positions Company for Most Aggressive Growth Phase to Date
Company Ships Over 250,000 SIM Cards and Secures $6 Million... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed | Enrollment in Both Dose Cohorts of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LINKHOME HOLDINGS INC finden Sie auf Wallstreet Online.